查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症基因治疗市场——全球行业规模、份额、趋势、机会、预测，2018-2028 年，按疗法、按适应症、按最终用户、按地区、竞争
市场调查报告书
商品编码
1255232

癌症基因治疗市场——全球行业规模、份额、趋势、机会、预测，2018-2028 年，按疗法、按适应症、按最终用户、按地区、竞争

Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapy, By Indication, By End User, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球癌症基因治疗市场预计在预测期内将出现令人瞩目的增长。

随着人们对低成本、低痛苦治疗的需求不断增加以及人们审美的不断提高，世界各个地区对癌症基因治疗的需求都大大增加。 此外，人们对基因治疗和诊断的好处的认识不断提高，全球癌症治疗的医疗保健支出不断增加，预计将在预测期内进一步推动癌症基因治疗市场的发展。 到 2022 年，估计美国将有 66,470 人（48,520 名男性和 17,950 名女性）被诊断出患有头颈癌。

启动研发活动

研发活动的增加和医疗保健基础设施的改善带来的技术进步是预测期内癌症基因治疗市场增长的主要驱动力。 政府机构专注于发达的基础设施以获得更高的利润。 伦理上可接受的癌症治疗的各种创新疗法和新产品的不断开发也有望在未来几年推动市场增长。 预计监管环境的改善将增加对癌症基因治疗的需求，并在预测期内推动市场增长。 生产商正在受到监管，以确保发布与消费者健康直接相关的无缺陷产品，这可能会推动未来几年的市场增长。 基因治疗产品的缺陷对患者来说可能是灾难性的，并且已经修改了几项法律以防止在上市后监督期间召回产品。 然而，未来几年癌症基因治疗市场的扩张将得益于高质量癌症基因疗法的日益普及。 到 2020 年，估计美国将诊断出 276,480 例浸润性乳腺癌新病例和 48,530 例原位乳腺癌新病例。

基因治疗的不断进步

预测期间，由于人口增长、过度饮酒、吸烟、低体力活动、高体重指数以及水果和蔬菜摄入量低，糖尿病和肥胖等生活方式相关疾病的患病率将进一步增加期间。预计将在市场上产生有利可图的增长。 2022 年 3 月，美国国家心肺血液研究所向印第安纳大学医学院的研究人员拨款 1200 万美元。 这笔赠款旨在开发一种更安全且具有潜在治愈性的基因治疗方法的关键组成部分，用于治疗血友病。 因此，各种私营公司和政府机构正在投资基因疗法以治愈世界各地的癌症疾病。 同样，对实验室自动化的需求不断增加以及对预防保健意识的提高一直是推动市场多年来增长的主要因素。 癌症患者人数的增加主要影响了该行业的发展，因为它是世界上第二大死因。 到 2020 年，估计美国将诊断出 1,806,590 例新癌症病例，606,520 例将死于该病。

近期发展

  • 2021 9 月，Adaptimmune 与 Genentech 合作开发了针对多种癌症适应症的同种异体细胞疗法。
  • 2021 年 6 月，Eisai和Bristol-Myers Squibb K.K.同意合作开发和商业化卫材的 ADC MORAb-202，用于治疗晚期实体恶性肿瘤。底部。
  • 2021 年 6 月 GSK 和 iTeos Therapeutics 合作开发 EOS-448，这是一种抗 TIGIT 单克隆抗体，之前在 Phase 1 阶段获批用于治疗晚期实体瘤，与

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第5章临床试验分析

  • 正在进行的临床试验
  • 已完成临床试验
  • 已完成临床试验
  • 管道细分，按开发阶段
  • 管道细分，按状态
  • 按研究类型划分的管道细分
  • 按地区划分的渠道细分
  • 临床试验热图

第6章全球癌症基因治疗市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过疗法（癌细胞疗法、基因引导的免疫疗法、基因转移等）
    • 按适应症（乳腺癌、卵巢癌、肺癌、肝癌、胰腺癌、前列腺癌等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图

第7章北美癌症基因治疗市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过治疗
    • 根据指示
    • 最终用户
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 加拿大
    • 墨西哥

第8章欧洲癌症基因治疗市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过治疗
    • 根据指示
    • 最终用户
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第9章亚太癌症基因治疗市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过治疗
    • 根据指示
    • 最终用户
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章南美癌症基因治疗市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过治疗
    • 根据指示
    • 最终用户
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章中东和非洲癌症基因治疗市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 通过治疗
    • 根据指示
    • 最终用户
    • 按国家
  • MEA：国家分析
    • 南非的癌症基因治疗
    • 沙特阿拉伯的癌症基因治疗
    • 阿联酋的癌症基因治疗

第 12 章市场动态

  • 司机
  • 任务

第13章市场趋势与发展

  • 近期趋势
  • 併购
  • 产品公告

第14章竞争格局

  • Abeona Therapeutics Inc.
  • Asklepios BioPharmaceutical Inc.
  • Altor Bioscience Inc.
  • Bluebird bio-Inc.
  • BioCancell Inc.
  • Celgene Inc.
  • Elevate Bio Inc.
  • GlaxoSmithKline Inc.
  • Genelux Corporation
  • Introgen Therapeutics Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Merck KGaA

第 15 章战略建议

简介目录
Product Code: 14340

The Global Cancer Gene Therapy Market is anticipated to witness impressive growth during the forecast period. Growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increases the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on cancer treatment across the globe, is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.

Increasing research and development activities

Increasing research and development activities and technological advancement with developed healthcare infrastructure is the major factor for the growth of the cancer gene therapy market during the forecast period. Government organizations are focusing on developed infrastructure with higher profit. Different type of innovative therapies is available for cancer therapy which is ethically acceptable, and the increasing development of new products are expected to boost the market growth over the years. The growing regulatory environment has enhanced the demand for cancer gene therapy which will boost market growth during the forecast period. Due to their direct connection to consumer health, regulations are placed on producers to assure the release of products that are free from flaws which can drive market growth over the years. Some laws have been changed to prevent product recalls during post-marketing surveillance since any flaws in gene therapy goods could be disastrous for patients. However, the expansion of the cancer gene therapy market in the years to come will be aided by the growing availability of high-quality cancer gene therapy. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer.

Growing advancement in gene therapy

The increasing prevalence rate of lifestyle disorders such as diabetes and obesity, excessive alcohol consumption, tobacco use, low physical activity, high body mass index, and low intake of fruits and vegetables because of the growing population is further expected to create a lucrative growth of the market during the forecast period. In march 2022, the National Heart, Lung, and Blood Institute granted USD 12 million to an Indiana University School of Medicine Researcher. This grant is for developing a major part of a gene therapy approach to safer and potentially curative treatments for hemophilia diseases. So different private and government organizations are investing in gene therapy for curing cancer diseases across the globe. Similarly, increasing demand for laboratory automation and growing awareness of preventative healthcare are the major factors that will boost the market growth over the years. The rise in cancer cases is primarily affecting the growth of the industry, being the second largest death cause in the world. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States, and 606,520 people will die from the disease.

Market Segmentation

The Global Cancer Gene Therapy Market can be segmented by therapy, indication, end user, and by region. Based on therapy, the market can be segmented into Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others. Based on indication, the market can be segmented into Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others. Based on the end user, the market can be differentiated by Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. Amongst the different countries, the United States dominates the global cancer gene therapy market on account of the growing demand for advanced therapy with low costs for curing cancer diseases in the country.

Recent Developments

  • In Sept 2021, Adaptimmune collaborated with Genentech to develop allogeneic cell therapies indicated for the treatment of multiple cancers.
  • In June 2021, Eisai and Bristol Myers Squibb agreed to partner for the development and commercialization of Eisai's ADC, MORAb-202, for the treatment of advanced solid malignancies.
  • In June 2021, GSK and iTeos Therapeutics partnered to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for the treatment of advanced solid malignancies.

Market Players

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA are some of the leading players operating in the Global Cancer Gene Therapy Market.

Report Scope

In this report, global cancer gene therapy systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Gene Therapy Market, By Therapy:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer
  • Others

Cancer Gene Therapy Market, By Indication:

  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Others

Cancer Gene Therapy Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Cancer Gene Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Gene Therapy Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Cancer Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
    • 6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
    • 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map

7. North America Cancer Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Cancer Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Cancer Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User

8. Europe Cancer Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Cancer Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Cancer Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Cancer Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Asia-Pacific Cancer Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. India Cancer Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Cancer Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Cancer Gene Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Cancer Gene Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By End User

10. South America Cancer Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Cancer Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Cancer Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Middle East and Africa Cancer Gene Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Gene Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Cancer Gene Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Abeona Therapeutics Inc.
    • 14.6.2. Asklepios BioPharmaceutical Inc.
    • 14.6.3. Altor Bioscience Inc.
    • 14.6.4. Bluebird bio-Inc.
    • 14.6.5. BioCancell Inc.
    • 14.6.6. Celgene Inc.
    • 14.6.7. Elevate Bio Inc.
    • 14.6.8. GlaxoSmithKline Inc.
    • 14.6.9. Genelux Corporation
    • 14.6.10. Introgen Therapeutics Inc.
    • 14.6.11. OncoGenex Pharmaceuticals Inc.
    • 14.6.12. Merck KGaA

15. Strategic Recommendations